Identity
- Security key
- 11993
- Ticker
- ATAI
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2021-06-18
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ATAI
Detail
Enriched 2026-08-14 20:47
- Market cap
- $2,681,351,556.87
- Shares outstanding (class)
- 368,166,674
- Shares outstanding (weighted)
- 370,864,669
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 99
- Location
- NEW YORK, NY
- Homepage
- https://www.ataibeckley.com
- Description
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.